|Ms. Emma Walmsley||Chief Exec. Officer and Director||N/A||N/A||47|
|Mr. Simon P. Dingemans||Chief Financial Officer and Exec. Director||1.89M||278.77k||53|
|Dr. Moncef M. Slaoui Ph.D.||Chairman of Global Vaccines and Advisor||4.34M||N/A||57|
|Dr. Patrick J. T. Vallance||Pres of R&D and Exec. Director||N/A||N/A||56|
|Mr. Daniel E. Troy||Sr. VP and Gen. Counsel||N/A||N/A||N/A|
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV, as well as oncology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories under the Otrivin, Panadol, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.
GlaxoSmithKline plc’s ISS Governance QualityScore as of May 1, 2017 is 8. The pillar scores are Audit: 10; Board: 1; Shareholder Rights: 1; Compensation: 1.